Lercanidipine Eg

Lercanidipine Hydrochloride, the active ingredient in Lercanidipine Eg, is a calcium channel blocker presented as a tablet for oral use. It lowers elevated blood pressure in adults with hypertension. GNH USA supplies Lercanidipine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Eg is a dihydropyridine calcium‑channel blocker used in the management of hypertension and related cardiovascular conditions.

- Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Hypertension with coronary artery disease: helps control blood pressure while improving coronary blood flow. - Hypertension in elderly patients: provides effective blood pressure reduction with once‑daily dosing.

Lercanidipine Eg may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: sensation of warmth, especially on the face. - Peripheral edema: swelling of the ankles or feet. - Dizziness or light‑headedness. - Fatigue: general feeling of tiredness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of lips, tongue, or throat. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with Lercanidipine Eg, consider the following safety measures.

- Renal impairment: adjust therapy if severe kidney disease is present. - Hepatic impairment: use with caution in patients with liver dysfunction. - Concomitant CYP3A4 inhibitors: monitor for increased drug exposure. - Pregnancy: avoid unless clearly needed; discuss risks with a healthcare professional. - Elderly patients: start at the lowest effective dose and monitor closely. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lercanidipine Eg can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma levels. - Grapefruit juice: can increase drug exposure and risk of hypotension. - Co‑administration with other calcium‑channel blockers: may cause additive vasodilation.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may enhance blood‑pressure lowering effect. - Diuretics: combined effect on blood pressure may require dose adjustment. - ACE inhibitors or ARBs: monitor for excessive hypotension. - Digoxin: increased risk of cardiac conduction abnormalities.